Author:
Tollens Fabian,Baltzer Pascal A.T.,Froelich Matthias F.,Kaiser Clemens G.
Abstract
BackgroundEconomic evaluations have become an accepted methodology for decision makers to allocate resources in healthcare systems. Particularly in screening, where short-term costs are associated with long-term benefits, and adverse effects of screening intermingle, cost-effectiveness analyses provide a means to estimate the economic value of screening.PurposeTo introduce the methodology of economic evaluations and to review the existing evidence on cost-effectiveness of MR-based breast cancer screening.Materials and methodsThe various concepts and techniques of economic evaluations critical to the interpretation of cost-effectiveness analyses are briefly introduced. In a systematic review of the literature, economic evaluations from the years 2000-2022 are reviewed.ResultsDespite a considerable heterogeneity in the reported input variables, outcome categories and methodological approaches, cost-effectiveness analyses report favorably on the economic value of breast MRI screening for different risk groups, including both short- and long-term costs and outcomes.ConclusionEconomic evaluations indicate a strongly favorable economic value of breast MRI screening for women at high risk and for women with dense breast tissue.
Reference93 articles.
1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin Mai,2021
2. Global cancer incidence and mortality rates and trends–an update;Torre;Cancer Epidemiol biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol,2016
3. SEER*Stat Database: Incidence - SEER Research Data, 9 Registries, Nov 2020 Sub (1975-2018) - Linked To County Attributes - Time Dependent (1990-2018) Income/Rurality, 1969-2019 Counties, National Cancer Institute, DCCPS, Surveillance Research Program2021
4. The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening;Tabár;Cancer,2019
5. Breast cancer screening: are we seeing the benefit;Puliti;BMC Med,2012